Atypical teratoid rhabdoid tumor medical therapy: Difference between revisions

Jump to navigation Jump to search
Aditya Govindavarjhulla (talk | contribs)
Created page with "===Chemotherapy options=== Approximately 50% of the AT/RTs will transiently respond, but Chemotherapy by itself is rarely curative. There is no standard treatment for AT/..."
 
Aditya Govindavarjhulla (talk | contribs)
No edit summary
Line 1: Line 1:
__NOTOC__
{{Atypical teratoid rhabdoid tumor}}
{{CMG}}
==Overview==
===Chemotherapy options===
===Chemotherapy options===
Approximately 50% of the AT/RTs will transiently respond, but [[Chemotherapy]] by itself is rarely curative.  There is no standard treatment for AT/RT.  Various chemotherapeutic agents have been used against AT/RTs which are also used against other CNS tumors including [[cisplatin]]um, [[carboplatinum]], [[cyclophosphamide]], [[vincristine]] and [[etoposide]].  Some [[chemotherapy regimens|Chemotherapy protocols]] are listed below:  
Approximately 50% of the AT/RTs will transiently respond, but [[Chemotherapy]] by itself is rarely curative.  There is no standard treatment for AT/RT.  Various chemotherapeutic agents have been used against AT/RTs which are also used against other CNS tumors including [[cisplatin]]um, [[carboplatinum]], [[cyclophosphamide]], [[vincristine]] and [[etoposide]].  Some [[chemotherapy regimens|Chemotherapy protocols]] are listed below:  
Line 9: Line 13:


* High dose chemotherapy with stem cell rescue. This therapy uses chemotherapy at doses high enough to completely suppress the [[bone marrow]].  Prior to instituting this therapy, the child has a [[Central venous catheter|central line]] placed and [[stem cell|stem cells]] are gathered.  After therapy these cells are given back to the child to [[Hematopoietic stem cell transplantation|regrow the bone marrow]].  Stem cell rescue or [[autologous]] [[bone marrow transplantation]], was initially thought to be of benefit to a wide group of patients, but has declined over the [[History of cancer chemotherapy|history of chemotherapy]] protocols.  A general description of stem cell rescue is available.<ref>{{cite web |url=http://www.cancerbackup.org.uk/Treatments/Stemcellbonemarrowtransplants/Generalinformation |title=Stem cell and bone marrow transplants|publisher= Cancerbackup |accessdate=2007-07-09 }}</ref>    In addition, there are some reports that it is effective with select cancers and this includes AT/RT.<ref>{{cite web |url=http://content.nejm.org/cgi/content/abstract/348/19/1875 |publisher=NEJM|title= High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma |accessdate=2007-07-09}}</ref>
* High dose chemotherapy with stem cell rescue. This therapy uses chemotherapy at doses high enough to completely suppress the [[bone marrow]].  Prior to instituting this therapy, the child has a [[Central venous catheter|central line]] placed and [[stem cell|stem cells]] are gathered.  After therapy these cells are given back to the child to [[Hematopoietic stem cell transplantation|regrow the bone marrow]].  Stem cell rescue or [[autologous]] [[bone marrow transplantation]], was initially thought to be of benefit to a wide group of patients, but has declined over the [[History of cancer chemotherapy|history of chemotherapy]] protocols.  A general description of stem cell rescue is available.<ref>{{cite web |url=http://www.cancerbackup.org.uk/Treatments/Stemcellbonemarrowtransplants/Generalinformation |title=Stem cell and bone marrow transplants|publisher= Cancerbackup |accessdate=2007-07-09 }}</ref>    In addition, there are some reports that it is effective with select cancers and this includes AT/RT.<ref>{{cite web |url=http://content.nejm.org/cgi/content/abstract/348/19/1875 |publisher=NEJM|title= High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma |accessdate=2007-07-09}}</ref>
==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Oncology]]
[[Category:Types of cancer]]
[[Category:Rare cancers]]
[[Category:Rare diseases]]
[[Category:Pathology]]
[[Category:Pediatrics]]
[[Category:Neurology]]
[[Category:Pediatric cancers]]
[[Category:Disease]]

Revision as of 19:36, 7 September 2012

Atypical teratoid rhabdoid tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atypical Teratoid Rhabdoid Tumor from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Atypical teratoid rhabdoid tumor medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atypical teratoid rhabdoid tumor medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atypical teratoid rhabdoid tumor medical therapy

CDC on Atypical teratoid rhabdoid tumor medical therapy

Atypical teratoid rhabdoid tumor medical therapy in the news

Blogs on Atypical teratoid rhabdoid tumor medical therapy

Directions to Hospitals Treating Atypical teratoid rhabdoid tumor

Risk calculators and risk factors for Atypical teratoid rhabdoid tumor medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Chemotherapy options

Approximately 50% of the AT/RTs will transiently respond, but Chemotherapy by itself is rarely curative. There is no standard treatment for AT/RT. Various chemotherapeutic agents have been used against AT/RTs which are also used against other CNS tumors including cisplatinum, carboplatinum, cyclophosphamide, vincristine and etoposide. Some Chemotherapy protocols are listed below:

  • CCG clinical trial CCG-9921 was activated in 1993 and published its results in 2005. The proposed treatments did not have different outcomes and were not an improvement on prior treatments.[1] Geyer published a review of chemotherapy on 299 infants with CNS tumors that evaluated response rate, event-free survival (EFS), and toxicity of two chemotherapeutic regimens for treatment of children younger than 36 months with malignant brain tumors. Patients were randomly assigned to one of two regimens of induction chemotherapy (vincristine, cisplatin, cyclophosphamide, and etoposide v vincristine, carboplatin, ifosfamide, and etoposide). Intensified induction chemotherapy resulted in a high response rate of malignant brain tumors in infants. Survival was comparable to that of previous studies, and most patients who survived did not receive radiation therapy.[1]
  • Sarcoma protocols. There has been at least one report in the literature of malignant rhabdoid tumors of the CNS being treated in as a high-grade intracranial sarcoma. These three cases were treated with surgery, chemotherapy, radiotherapy and triple intrathecal chemotherapy similar to the Intergroup Rhadbdomyoscarcoma Study III guidelines.[2]
  • Intrathecal protocols. One of the difficulties with brain and spinal tumors is that the blood brain barrier needs to be crossed so that the drug can get to the tumor. One mechanism to deliver the drug is through a device called an Ommaya reservoir. This is a device which shares some characteristics with a shunt in which a tube a surgically placed in the fluid surrounding the brain and a bulb shaped reservoir attached to the tubing is placed under the skin of the scalp. When the child is to receive intrathecal chemotherapy, the drug is administered into this bulb reservoir. At other times intrathecal chemotherapeutic agents are delivered through a lumbar puncture (spinal tap). A current Pediatric Brain Tumor Consortium Protocol uses intrathecal mafosfamide, a pre-activated cyclophosphamidederivative, in addition to other modalities to try to effect this tumor.[3]
  • High dose chemotherapy with stem cell rescue. This therapy uses chemotherapy at doses high enough to completely suppress the bone marrow. Prior to instituting this therapy, the child has a central line placed and stem cells are gathered. After therapy these cells are given back to the child to regrow the bone marrow. Stem cell rescue or autologous bone marrow transplantation, was initially thought to be of benefit to a wide group of patients, but has declined over the history of chemotherapy protocols. A general description of stem cell rescue is available.[4] In addition, there are some reports that it is effective with select cancers and this includes AT/RT.[5]

References

  1. 1.0 1.1 Geyer JR, Sposto R, Jennings M; et al. (2005). "Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group". J. Clin. Oncol. 23 (30): 7621–31. doi:10.1200/JCO.2005.09.095. PMID 16234523.
  2. "Childhood Rhabdomyosarcoma Treatment". National Cancer Institute. Retrieved 2007-07-09.
  3. Poussaint TY, Phillips PC, Vajapeyam S; et al. (2007). "The Neuroimaging Center of the Pediatric Brain Tumor Consortium-collaborative neuroimaging in pediatric brain tumor research: a work in progress". AJNR. American journal of neuroradiology. 28 (4): 603–7. PMID 17416804.
  4. "Stem cell and bone marrow transplants". Cancerbackup. Retrieved 2007-07-09.
  5. "High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma". NEJM. Retrieved 2007-07-09.

Template:WH Template:WS